> Detailanzeige

Benz, Matthias R.; Czernin, Johannes; Allen‐Auerbach, Martin S.; Dry, Sarah M.; Sutthiruangwong, Piriya; Spick, Claudio; Radu, Caius; Weber, Wolfgang A.; Tap, William D.; Eilber, Fritz C.

3′‐deoxy‐3′‐[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma : A pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki‐67 activity and histopathologic response : A pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki‐67 activity and histopathologic response

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: 3′‐deoxy‐3′‐[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma : A pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki‐67 activity and histopathologic response : A pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki‐67 activity and histopathologic response
  • Beteiligte: Benz, Matthias R.; Czernin, Johannes; Allen‐Auerbach, Martin S.; Dry, Sarah M.; Sutthiruangwong, Piriya; Spick, Claudio; Radu, Caius; Weber, Wolfgang A.; Tap, William D.; Eilber, Fritz C.
  • Erschienen: Wiley, 2012
  • Erschienen in: Cancer
  • Sprache: Englisch
  • DOI: 10.1002/cncr.26630
  • ISSN: 0008-543X; 1097-0142
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec><jats:title>BACKGROUND:</jats:title><jats:p>This study sought to determine whether [<jats:sup>18</jats:sup>F]fluorothymidine (FLT) positron emission tomography (PET)/computed tomography (CT) imaging allows assessment of tumor viability and proliferation in patients with soft tissue sarcomas who are treated with neoadjuvant therapy.</jats:p></jats:sec><jats:sec><jats:title>METHODS:</jats:title><jats:p>Twenty patients with biopsy‐proven, resectable, high‐grade soft tissue sarcoma underwent [<jats:sup>18</jats:sup>F]FLT PET/CT imaging before and after neoadjuvant therapy. Histologic subtypes included sarcomas not otherwise specified (n = 5), malignant peripheral nerve sheath tumors (n = 3), gastrointestinal stromal tumors (n = 3), leiomyosarcomas (n = 3), angiosarcomas (n = 2), and others (n = 4). Changes in [<jats:sup>18</jats:sup>F]FLT peak standardized uptake value (SUVpeak) were correlated with percent necrosis in excised tissue, whereas posttreatment [<jats:sup>18</jats:sup>F]FLT tumor uptake was correlated with thymidine kinase 1 (TK1) expression and Ki‐67 staining indices in excised tumor tissue.</jats:p></jats:sec><jats:sec><jats:title>RESULTS:</jats:title><jats:p>Tumor FLT SUVpeak averaged 7.1 ± 3.7 g/mL (range, 1.9‐16.1 g/mL) at baseline and decreased significantly to 2.7 ± 1.6 g/mL (range, 0.8‐6.0 g/mL) at follow‐up (<jats:italic>P</jats:italic> &lt; .001); however, marked reductions in SUV were not specific for histopathological response. The posttreatment SUVpeak did not correlate with TK1 (<jats:italic>P</jats:italic> = .27) or Ki‐67 expression (<jats:italic>P</jats:italic> = .21).</jats:p></jats:sec><jats:sec><jats:title>CONCLUSIONS:</jats:title><jats:p>Marked reductions in [<jats:sup>18</jats:sup>F]FLT tumor uptake in response to neoadjuvant treatment were observed in most patients with sarcoma. However, these reductions were not specific for histopathologic response to neoadjuvant therapy. Furthermore, posttreatment [<jats:sup>18</jats:sup>F]FLT tumor uptake was unrelated to tumor proliferation by Ki‐67 and TK1 staining. These results question the value of [<jats:sup>18</jats:sup>F]FLT PET imaging for treatment response assessments in patients with soft tissue sarcoma. Cancer 2012;118: 3135–44. © 2011 American Cancer Society.</jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang